A candidate drug developed by Umecrine Mood AB to treat premenstrual dysphoric disorder (PMDD) showed positive results during a randomized Phase I/II study.
Those taking the drug called UC1010 showed a significant reduction in PMDD symptoms compared to those taking a placebo. “UC1010 has been developed specifically to target the atypical effects of progesterone metabolites on GABA-A receptor activity in the brain, believed to underlie key PMDD symptoms,” according to Umecrine Mood AB.
While most women experience some form of premenstrual discomfort, about 5 percent of young and middle-aged women experience PMDD, which has more severe symptoms. In some cases symptoms are so debilitating that normal activities are disrupted and the costs to society are huge.